BHR Pharma, LLC: Clinical Trials

5 trials sponsored by BHR Pharma, LLC, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated, 2 completed. 3 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Terminated 2, Completed 1
Phase 22Completed 1, Terminated 1

Follow BHR Pharma, LLC: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue
4-OH tamoxifen, Placebo - Mammographic Breast Density
Phase 3TerminatedBHR Pharma, LLC2232017-08-212022-07-26
Study of Progesterone in Treatment of Vasomotor Symptoms
Progesterone oral capsule, Placebo oral capsule - Menopause Related Conditions
Phase 3TerminatedBHR Pharma, LLC552017-08-012019-03-06
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Afimoxifene, Laboratory Biomarker Analysis, Placebo - Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Phase 2CompletedNorthwestern University1002017-05-312024-12-18
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo - Cancer of the Prostate
Phase 2TerminatedBHR Pharma, LLC342015-07-012022-03-31
Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury
Progesterone, Lipid emulsion without progesterone - Brain Injuries
Phase 3CompletedBHR Pharma, LLC11952010-06-012024-10-02

Conditions studied

Brain Injuries (1)  ·  Carcinoma, Intraductal, Noninfiltrating (1)  ·  Prostatic Neoplasms (1)  ·  Wounds and Injuries (1)

Interventions

4,17 beta-dihydroxy-4-androstene-3-one (2)  ·  Progesterone (2)  ·  Tamoxifen (1)  ·  afimoxifene (1)

Countries

United States (4)  ·  Germany (3)  ·  Spain (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  China (1)  ·  Czechia (1)  ·  Finland (1)  ·  France (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Netherlands (1)

Top investigators

Neta R. Nelson, MPH (1)  ·  Seema Khan, MD (1)

Results publications

PMID 25493978, PMID 37870954

NIH funding

N01CN00035 (1), P30CA060553 (1)